# US 5,631,006 A · Immunotherapy protocol of culturing leukocytes in the presence of interleukin-2 in a hollow fiber cartridge

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,631,006 A
- Document ID: US5631006A
- Status: Granted
- Kind: A
- Application number: 08/483,876
- Filed: 1995-06-07
- Granted: 1997-05-20
- Earliest claimed: 1986-04-28
- Assignees: Endotronics, Inc.
- Inventors: Georgiann B. Melink; Raji A. Shankar
- Web page: https://patentgrep.com/patent/US5631006A

## CPC

- C12M 25/10: {Hollow fibers or tubes (hollow fiber modules in general B01D63/02)}
- C12M 29/16: {Hollow fibers (hollow fiber modules in general B01D63/02)}
- C12N 5/0636: {T lymphocytes}
- C12N 2501/23: Interleukins [IL]
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An immunotherapy protocol in which leukocytes are cultured in the presence of interleukin-2 in a hollow fiber cartridge perfusion system for at least four days to achieve a harvest yield of at least 100% of leukocytes with respect to the number of cells initially present in the hollow cartridge, and where the leukocytes have a lytic activity at least equal to that of cells grown in a static culturing system and where the lytic activity of the cells following the culture period in the hollow fiber is at least equal to cells grown in a static culturing system.

## Claims

### Claim 1

An immunotherapy protocol comprising:
culturing leukocytes at a high density of about 8.times.10.sup.7 cells per ml in the presence of recombinant interleukin-2, in a hollow fiber cartridge for at least four days to obtain a cell harvest having a yield of at least 100% with respect to the number of cells initially present in the hollow fiber cartridge, wherein the cultured leukocytes have a lyric activity approximately equal to or greater than that of leukocytes cultured in a static culturing system, and administering said cultured leukocytes to a patient in need of said immunotherapy.

### Claim 2 (depends on 1)

The protocol of claim 1, wherein said protocol comprises culturing said leukocytes in the presence of said recombinant interleukin-2 by circulating culture medium through the lumens of said hollow fiber cartridge and simultaneously circulating culture medium and said lymphokine through the extracapillary space in said hollow fiber cartridge surrounding said lumens of said hollow fibers and containing said leukocytes.

### Claim 3 (depends on 2)

The protocol of claim 2, wherein said hollow fibers of said hollow fiber cartridge have membrane walls with a selective molecular weight cut off of less than 50,000 Daltons.

### Claim 4 (depends on 3)

The protocol of claim 3, wherein said molecular weight cut off is a cut off of less than 15,000 Daltons.

### Claim 5 (depends on 1)

The protocol of claim 1, wherein said method comprises said culturing for at least five days to obtain a cell harvest having a yield of at least 150%, with respect to the number of cells seeded in the hollow fiber cartridge.
